Iterum shareholders reject all four EGM proposals; company warns of possible wind-down

Iterum Therapeutics plc

Shareholders voted against increasing authorized share capital (12.8M for vs 17.9M against).
Reverse share split proposal also defeated: 13.9M for vs 16.7M against.
Directors' allotment authority and pre-emption opt-out similarly rejected.
Company says vote results restrict ability to raise capital, harming operations and going concern.
Management warns of possible wind-down, bankruptcy, or liquidation; shareholders unlikely to receive distribution.

item 5.07 item 8.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-057393
form_type: 8-K
ticker: ITRMF
cik: 0001659323
company_name: Iterum Therapeutics plc
filed_at: 2026-02-18T23:59:59+00:00
discovered_at: 2026-05-14T18:02:35.790430+00:00
generated_at: 2026-05-16T02:06:04.327695+00:00
sec_items: ["5.07", "8.01"]
event_type: other_material
sentiment: negative
materiality_score: 1.0
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-057393
json_url: https://secwatch.observer/filing/0001193125-26-057393.json
markdown_url: https://secwatch.observer/filing/0001193125-26-057393.md
text_url: https://secwatch.observer/filing/0001193125-26-057393.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1659323/000119312526057393/0001193125-26-057393-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1659323/000119312526057393/itrm-20260218.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-057393

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.